Notice2025-10919
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 16, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 114 (Monday, June 16, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 114 (Monday, June 16, 2025)]
[Notices]
[Page 25348]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-10919]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Terrence Joyce at 240-987-2347, or
<a href="/cdn-cgi/l/email-protection#c0b4a5b2b2a5aea3a5eeaaafb9a3a580aea9a8eea7afb6"><span class="__cf_email__" data-cfemail="dca8b9aeaeb9b2bfb9f2b6b3a5bfb99cb2b5b4f2bbb3aa">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Francisella Lipids as Broad Anti-Inflammatory Therapeutics
Description of Technology
Anti-inflammatory treatments, particularly those used in the
context of viral infection, have been shown to greatly inhibit the
overall immune response, which can result in poor immunity and failure
to control or clear the infection. Novel alternatives that can
effectively attenuate inflammation without the more serious side
effects of steroid medications (e.g., global immune suppression, muscle
weakness, etc.) may have substantial use across a wide range of disease
areas.
Francisella tularensis (FT), the causative agent of tularemia,
exhibits a potent ability to induce rapid suppression of inflammatory
responses in host cells. Building on prior work that demonstrated the
ability of crude and enriched lipids from virulent FT strains to dampen
inflammation triggered by a variety of sources, researchers at the
National Institute of Allergy and Infectious Disease (NIAID) have
developed FT lipid preparations with strong potential for the
prophylactic/therapeutic treatment of viral-mediated inflammation--
without deleterious effects on the development of anti-viral immunity.
The NIAID data further show that these FT lipid preparations are
relatively non-toxic to cells, do not adversely affect the functioning
of T cells, and act in part by inhibiting production of inflammatory
mediators, highlighting other potential therapeutic targets such as
allergic and autoimmune-associated inflammation.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications:
<bullet> Well-tolerated, short-term prophylactic or therapeutic
treatment of inflammation across multiple disease areas (viral
infection, autoimmunity, etc.)
Competitive Advantages:
<bullet> Potential alternative that can overcome compromises to
immunity and other side effects associated with traditional anti-
inflammatory treatment
Development Stage: Preclinical.
Relevant Publications:
<bullet> Crane DD, et al. Lipids derived from virulent Francisella
tularensis broadly inhibit pulmonary inflammation via toll-like
receptor 2 and peroxisome proliferator-activated receptor [alpha]. Clin
Vaccine Immunol. 2013;20(10):1531-1540.
<bullet> Ireland R, et al. Francisella tularensis SchuS4 and SchuS4
lipids inhibit IL-12p40 in primary human dendritic cells by inhibition
of IRF1 and IRF8. J Immunol. 2013;191(3):1276-1286.
Inventors: Catherine Bosio, Glenn Nardone, Robin Ireland (all of
NIAID)
Intellectual Property: HHS Reference No. E-142-2016; Provisional
Patent Application 62/319,692, filed on April 7, 2016; 16,091,768,
filed on October 5, 2018, issued December 20, 2022; PCT Application No.
PCT/US2017/026467, filed on April 6, 2017; European Patent App. No
17721893.0, filed on April 6, 2017.
Licensing Contact: To license this technology, please contact
Terrence Joyce at 240-987-2347 or <a href="/cdn-cgi/l/email-protection#1a6e7f68687f74797f34707563797f5a747372347d756c"><span class="__cf_email__" data-cfemail="6511001717000b06004b0f0a1c0600250b0c0d4b020a13">[email protected]</span></a>, and reference
E-142-2016.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Terrence Joyce at 240-987-2347 or
<a href="/cdn-cgi/l/email-protection#661203141403080503480c091f050326080f0e48010910"><span class="__cf_email__" data-cfemail="b6c2d3c4c4d3d8d5d398dcd9cfd5d3f6d8dfde98d1d9c0">[email protected]</span></a>, and reference E-142-2016.
Dated: June 9, 2025.
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2025-10919 Filed 6-13-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 16, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.